Xeljanz, also known as tofacitinib, is a Janus kinase (JAK) inhibitor used to treat conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The price of Xeljanz 5 mg can vary significantly.
How Much Does Xeljanz 5 mg Cost?
The out-of-pocket cost for a 30-day supply of Xeljanz 5 mg can range widely, with some sources indicating costs as high as $5,000 to over $6,000. Factors influencing the price include the pharmacy, insurance coverage, and any available discount programs. For example, a 30-day supply of 5 mg Xeljanz tablets has been listed around $5,600 [1]. Prices can fluctuate, and obtaining a precise cost often requires checking with specific pharmacies or insurers.
What Factors Influence Xeljanz Pricing?
Several elements contribute to the cost of Xeljanz 5 mg. These include the manufacturing costs, research and development expenses incurred by the pharmaceutical company, market demand, and the pricing strategies of the manufacturer, Pfizer. Additionally, insurance formularies and patient assistance programs can significantly alter the final price paid by an individual. Competition from other medications in the same therapeutic class can also play a role in pricing.
Are There Patient Assistance Programs for Xeljanz?
Yes, Pfizer offers patient assistance programs that can help reduce the cost of Xeljanz for eligible individuals. The Pfizer RxPathways program provides access to medicines for people without prescription drug coverage or those facing financial hardship [2]. Details on eligibility and how to apply are available through Pfizer's official channels.
How Does Xeljanz Compare to Other Treatments for Arthritis?
Xeljanz belongs to a class of drugs known as JAK inhibitors, which work by blocking specific enzymes involved in inflammation. Other treatment options for rheumatoid arthritis and psoriatic arthritis include other JAK inhibitors, disease-modifying antirheumatic drugs (DMARDs) like methotrexate, and biologic therapies. The choice of treatment depends on the specific condition, its severity, a patient's medical history, and response to previous therapies. Pricing and insurance coverage also play a role in treatment selection.
When Does the Patent for Xeljanz Expire?
Information regarding specific patent expiry dates for Xeljanz is complex and often involves multiple patents covering different aspects of the drug, such as its formulation, method of use, and manufacturing process. DrugPatentWatch.com provides resources for tracking patent information for pharmaceuticals [3]. Generally, patents for major drugs can last up to 20 years from the filing date, but extensions and legal challenges can alter these timelines. The expiry of primary patents often opens the door for the development and approval of generic versions.
What Are the Side Effects of Xeljanz?
Common side effects associated with Xeljanz can include upper respiratory tract infections, headache, and diarrhea. More serious potential side effects may involve an increased risk of serious infections, blood clots, heart attack, stroke, and certain types of cancer. Patients are advised to discuss all potential risks and benefits with their healthcare provider.
Can Generic Versions of Xeljanz Be Available?
The availability of generic versions of Xeljanz depends on the expiration of its patents and regulatory approval from agencies like the U.S. Food and Drug Administration (FDA). Once key patents expire and generic manufacturers receive approval, lower-cost generic alternatives can enter the market, potentially impacting the price of the brand-name drug.
---
Sources:
[1] GoodRx. "Xeljanz Prices, Coupons & Patient Assistance Programs." https://www.goodrx.com/xeljanz
[2] Pfizer. "Pfizer RxPathways." https://www.pfizerpathways.com/
[3] DrugPatentWatch.com. "Xeljanz (Tofacitinib)." https://drugpatentwatch.com/search?drug_name=Xeljanz